- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Biosergen AB - Removal from trading on Nasdaq First North Growth Market | 278 | GlobeNewswire | On September 17, 2026, Nasdaq Stockholm AB decided, conditional upon the Swedish Companies Registration Office's authorization to implement the merger plan between Biosergen AB and Flerie AB, to... ► Artikel lesen | |
| Fr | BIOSERGEN AB: The Swedish Companies Registration Office has granted permission to implement the merger plan between Flerie and Biosergen | 1 | Cision News | ||
| Fr | Flerie AB: The Swedish Companies Registration Office has granted permission to implement the merger plan between Flerie and Biosergen | 211 | GlobeNewswire (Europe) | THIS ANNOUNCEMENT SHOULD NOT BE DISTRIBUTED, WHETHER DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, JAPAN, NEW ZEALAND, SOUTH AFRICA OR THE UNITED STATES OF AMERICA. THIS ANNOUNCEMENT SHOULD... ► Artikel lesen | |
| BIOSERGEN Aktie jetzt für 0€ handeln | |||||
| 17.09. | Biosergen AB - Removal from trading on Nasdaq First North Growth Market | 445 | GlobeNewswire | Biosergen AB has applied for its shares to be removed from trading on Nasdaq First North Growth Market.
Conditional upon the Swedish Companies Registration Office's authorization to implement... ► Artikel lesen | |
| 17.09. | Biosergen AB: Nasdaq approves Biosergen's application for delisting from First North Growth Market conditional upon the Swedish Companies Registration Office granting permission to execute the merger with Flerie | 350 | GlobeNewswire (Europe) | Biosergen AB ("Biosergen" or the "Company") applied on 15 September 2026 for delisting of the Company's shares from Nasdaq First North Growth Market, in connection with the contemplated merger between... ► Artikel lesen | |
| 15.09. | Biosergen AB: Biosergen applies for delisting of the company's shares from Nasdaq First North Growth Market conditional upon completion of the merger with Flerie | 252 | GlobeNewswire (Europe) | The Board of Directors of Biosergen AB ("Biosergen" or the "Company") has today, on 15 September 2026, in connection with the contemplated merger between Biosergen and Flerie AB (publ) ("Flerie") (the... ► Artikel lesen | |
| 10.09. | Biosergen AB: Biosergen resolves on a set-off issue to guarantors in connection with the completed rights issue | 173 | GlobeNewswire (Europe) | The Board of Directors of Biosergen AB (publ) ("Biosergen" or the "Company") has today, on 10 September 2026, pursuant to the authorisation granted by the extraordinary general meeting held on 6 August... ► Artikel lesen | |
| 28.08. | Biosergen AB: Biosergen's Rights Issue Oversubscribed | 438 | GlobeNewswire (Europe) | Biosergen AB (publ) ("Biosergen" or the "Company") today announces the outcome of the rights issue of shares (the "Rights Issue") for which the subscription period ended on 26 August 2026. The final... ► Artikel lesen | |
| 19.08. | Biosergen AB: Biosergen publishes interim report for the first half year 2026 | 350 | GlobeNewswire (Europe) | Biosergen Secures Funding Through Planned Merger Together with Flerie
August 19, 2026: Biosergen AB ("Biosergen" or the "Company") hereby publishes the interim report for the first half of 2026. The... ► Artikel lesen | |
| 11.08. | Listing of subscription rights and paid subscription shares of Biosergen AB | 515 | GlobeNewswire | With effect from August 12, 2026, the subscription rights in Biosergen AB will be traded on First North Growth Market. Trading will continue up until and including August 21, 2026.
... ► Artikel lesen | |
| 10.08. | Biosergen AB: Biosergen publishes information document regarding rights issue | 424 | GlobeNewswire (Europe) | The Board of Directors of Biosergen AB (publ) ("Biosergen" or the "Company") has today, on 10 August 2026, published an information document in connection with the rights issue of shares of approximately... ► Artikel lesen | |
| 06.08. | Biosergen AB: Bulletin from the extraordinary general meeting of Biosergen AB (publ) | 390 | GlobeNewswire (Europe) | Biosergen AB, reg. no. 559304-1295 ("Biosergen" or the "Company"), held its extraordinary general meeting today, 6 August 2026, at BAHR Advokatbyrå, Birger Jarlsgatan 16, 114 34 Stockholm, where the... ► Artikel lesen | |
| 06.08. | XFRA CAPITAL ADJUSTMENT INFORMATION - 06.08.2026 | 450 | Xetra Newsboard | Das Instrument W1M SG1J24887775 SINGAPORE SHIPPING SD-,1 EQUITY wird cum Kapitalmassnahme gehandelt am 06.08.2026 und ex Kapitalmassnahme am 07.08.2026 The instrument W1M SG1J24887775 SINGAPORE SHIPPING... ► Artikel lesen | |
| 16.07. | BIOSERGEN AB: Flerie publishes merger document | 8 | Cision News | ||
| 08.07. | Notice of extraordinary general meeting in Biosergen AB | 2 | Cision News | ||
| 30.06. | Biosergen AB: Bulletin from the annual general meeting of Biosergen AB | 260 | GlobeNewswire (Europe) | Biosergen AB reg. no. 559304-1295 ("Biosergen" or the "Company") held its annual general meeting today, 30 June 2026, at BAHR Advokatbyrå, Birger Jarlsgatan 16, 114 34 Stockholm, where the below resolutions... ► Artikel lesen | |
| 29.06. | The observation status for Biosergen AB is updated | 361 | GlobeNewswire | On April 10, 2026, the shares in Biosergen AB (the "Company") were given observation status with reference to information that the Company's board of directors had resolved to pause the development... ► Artikel lesen | |
| 26.06. | Biosergen AB: Statement from the Board of Directors of Biosergen regarding the merger with Flerie | 1.209 | GlobeNewswire (Europe) | This statement is made by the Board of Directors of Biosergen AB (the "Company" or "Biosergen") pursuant to Section II.19 of the Swedish takeover rules for certain trading platforms (the "Takeover... ► Artikel lesen | |
| 26.06. | Biosergen AB: The Board of Directors of Biosergen has resolved on a rights issue of shares of approximately SEK 40 million in connection with the merger with Flerie | 428 | GlobeNewswire (Europe) | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, WHETHER DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE,... ► Artikel lesen | |
| 26.06. | BIOSERGEN AB: Biosergen Publishes 2025 Annual Report | 1 | Cision News |
1 2 Weiter >>
31 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 41,030 | -0,24 % | QIAGEN N.V.: QIAGEN Convenes Global Tuberculosis Experts as New Pressures Challenge Progress Against Tuberculosis | Global TB Summit brings together international experts as persistent disease burden and funding pressures challenge progress against tuberculosis QuantiFERON-TB Gold Plus detects tuberculosis... ► Artikel lesen | |
| IMMUNOVANT | 26,730 | 0,00 % | Immunovant Q1 2027 Earnings Call: Complete Transcript | ||
| RECURSION PHARMACEUTICALS | 3,465 | 0,00 % | Recursion Pharmaceuticals (RXRX) Stock is Trending After Hours: Here's What You Should Know | ||
| PRAXIS PRECISION MEDICINES | 241,79 | +0,01 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 37,320 | 0,00 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Appoints Kristine Ball to Board of Directors Ahead of Planned Phase 3 Trial Initiation this Year | Accomplished biopharmaceutical executive with extensive experience in corporate strategy, finance and commercial readiness
Enliven continues preparation for late-stage... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 37,950 | 0,00 % | HRMY Stock Gains 27.6% in Six Months: Is There More Room for Growth? | ||
| ERASCA | 13,375 | -0,11 % | Erasca drops after sacking COO | ||
| MODERNA | 193,00 | -0,52 % | Moderna-Aktie: +14% an einem Tag - was treibt den Kurs? | Moderna hat am Freitag einen der stärksten Handelstage des Jahres hingelegt. Die Aktie sprang um +14,2% auf 225 US$ und markierte damit gleichzeitig ein neues 52-Wochen-Hoch. Rückenwind kam von neuen... ► Artikel lesen | |
| COGENT BIOSCIENCES | 29,550 | +0,10 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) | NDA supported by positive results from the APEX pivotal trial demonstrating clinically meaningful responses and evidence of disease modification in patients with AdvSM PDUFA target action date set... ► Artikel lesen | |
| NURIX THERAPEUTICS | 24,400 | 0,00 % | Nurix Therapeutics Swings To Profit In Q3 On Roche Licensing Revenue | SOUTH SAN FRANCISCO (dpa-AFX) - Nurix Therapeutics, Inc. (NRIX), clinical-stage biopharmaceutical company, reported a swing to profit in the third quarter from a loss in the year-ago period... ► Artikel lesen | |
| TANGO THERAPEUTICS | 22,050 | +0,05 % | Tango Therapeutics, Inc.: Tango Therapeutics to Present Updated Vopimetostat + RAS(ON) Combination Data at European Society For Medical Oncology (ESMO) Congress 2026 | ||
| TARSUS PHARMACEUTICALS | 68,06 | -0,01 % | Tarsus Pharmaceuticals, Inc: Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care | Adds gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational medicine designed to target the underlying biology of Stargardt's disease, a potentially blinding disease with no FDA-approved... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 28,840 | +0,07 % | Why Is Arcutis Biotherapeutics Stock Surging Thursday? | ||
| CITY THERAPEUTICS | 22,030 | -1,65 % | US IPO Weekly Recap: Biotechs City Therapeutics and Iambic headline the week's pricings | ||
| SUMMIT THERAPEUTICS | 14,650 | +0,14 % | Summit Therapeutics Secures $2B Strategic Investment From AstraZeneca | LONDON (dpa-AFX) - Summit Therapeutics Inc. (SMMT) on Monday announced the closing of AstraZeneca's (AZN) $2 billion strategic equity investment, which will support accelerated development of... ► Artikel lesen |
Das Unternehmen BIOSERGEN AB kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,042 Euro und damit +2,44 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOSERGEN AB finden Sie auf Wallstreet Online.